Every 10-Q that AVENUE THERAPEUTICS INC (ATXI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATXI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATXI filings page.
Avenue Therapeutics, a neurology-focused specialty pharmaceutical company, reported Q2 2026 net loss of $690k with no revenue, versus a prior-year profit driven by a $1.4M one-time AJ201 license termination payment. For the first half, net loss was $1.4M, slightly lower than $1.5M a year earlier as expenses fell.
R&D expense was $0.2M in Q2 and $0.4M year-to-date; G&A dropped to $0.5M in Q2 and $1.0M for six months as legal and personnel costs declined after 2025 activity. At June 30, 2026, cash was $1.9M, total assets $2.0M, liabilities $1.4M and equity $0.6M, with an accumulated deficit of $106.9M.
Net cash used in operations was $0.9M in the first half. Management states that substantial doubt exists about continuing as a going concern within 12 months without new capital, citing recurring losses, limited cash, loss of Nasdaq listing, and ineligibility to use its Form S-3 shelf and ATM facility, leaving the company dependent on equity, debt or partnerships.
Pipeline work continued. Avenue licensed ATX-04 from Duke for Pompe disease, with up to $15.6M in potential milestones and low single-digit royalties, and is preparing a pivotal-study plan after a pre-IND meeting. For IV tramadol, it has FDA agreement on a 300-patient Phase 3 safety non-inferiority trial, but initiation depends on securing financing or a partner.
Avenue Therapeutics reported a smaller quarterly net loss while continuing to face serious funding pressure. For the quarter ended March 31, 2026, the company lost about $0.7 million, compared with $1.9 million a year earlier, as operating expenses fell sharply.
Cash and cash equivalents were $2.4 million, down from $2.9 million at year-end, and management states there is substantial doubt about Avenue’s ability to continue as a going concern without new financing. The company licensed ATX‑04 from Duke University for Pompe disease and is preparing for a pivotal program, while also evaluating a Phase 3 safety study for IV tramadol that will require additional capital or a partner.
Avenue Therapeutics (ATXI) reported Q3 2025 results showing a net loss of $0.7 million, narrowing from the prior year. For the nine months, net loss was $2.2 million. Operating expenses fell sharply in Q3 to $0.7 million (R&D $0.18 million; G&A $0.55 million) versus $3.2 million a year ago. The company recognized $1.4 million of other revenue year-to-date tied to the AnnJi AJ201 termination and program transfer.
Cash and cash equivalents were $3.709 million at September 30, 2025. Avenue raised $2.094 million earlier in 2025 via its ATM before losing Nasdaq eligibility; the stock now trades on the OTC market. Management disclosed substantial doubt about the ability to continue as a going concern and said additional financing is needed to support a potential Phase 3 safety study of IV tramadol.
Shares outstanding were 3,183,558 as of November 12, 2025. Subsequent to quarter-end, Avenue sold Baergic to Axsome for $0.3 million upfront plus potential milestones and royalties.